These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 15194582)

  • 1. Relationship between inflammation and joint destruction in early rheumatoid arthritis: a mathematical description.
    Wick MC; Lindblad S; Klareskog L; Van Vollenhoven RF
    Ann Rheum Dis; 2004 Jul; 63(7):848-52. PubMed ID: 15194582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
    Svensson B; Boonen A; Albertsson K; van der Heijde D; Keller C; Hafström I
    Arthritis Rheum; 2005 Nov; 52(11):3360-70. PubMed ID: 16255010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient management of rheumatoid arthritis significantly reduces long-term functional disability.
    Tanaka E; Mannalithara A; Inoue E; Hara M; Tomatsu T; Kamatani N; Singh G; Yamanaka H
    Ann Rheum Dis; 2008 Aug; 67(8):1153-8. PubMed ID: 17971459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression.
    Hakala M; Risteli J; Aman S; Kautiainen H; Korpela M; Hannonen P; Leirisalo-Repo M; Laasonen L; Paimela L; Möttönen T;
    Scand J Rheumatol; 2008; 37(2):90-3. PubMed ID: 18415764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
    de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
    Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis.
    van der Helm-van Mil AH; van der Kooij SM; Allaart CF; Toes RE; Huizinga TW
    Ann Rheum Dis; 2008 Jun; 67(6):769-74. PubMed ID: 17965124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibodies against mutated citrullinated vimentin are a better predictor of disease activity at 24 months in early rheumatoid arthritis than antibodies against cyclic citrullinated peptides.
    Innala L; Kokkonen H; Eriksson C; Jidell E; Berglin E; Dahlqvst SR
    J Rheumatol; 2008 Jun; 35(6):1002-8. PubMed ID: 18398946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New therapeutic strategy of rheumatoid arthritis to reach the goal of suppression of joint destruction].
    Yamaguchi Y; Yamamoto K
    Clin Calcium; 2007 Apr; 17(4):463-73. PubMed ID: 17404474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early prediction of joint destruction in rheumatoid arthritis].
    Eguchi K
    Clin Calcium; 2007 Apr; 17(4):517-25. PubMed ID: 17404480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Invasiveness of fibroblast-like synoviocytes is an individual patient characteristic associated with the rate of joint destruction in patients with rheumatoid arthritis.
    Tolboom TC; van der Helm-Van Mil AH; Nelissen RG; Breedveld FC; Toes RE; Huizinga TW
    Arthritis Rheum; 2005 Jul; 52(7):1999-2002. PubMed ID: 15986342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis.
    Nyhäll-Wåhlin BM; Petersson IF; Nilsson JA; Jacobsson LT; Turesson C;
    Rheumatology (Oxford); 2009 Apr; 48(4):416-20. PubMed ID: 19213849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis.
    Verschueren P; Esselens G; Westhovens R
    Rheumatology (Oxford); 2008 Jan; 47(1):59-64. PubMed ID: 18039681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
    Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
    Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and extensive erosiveness in peripheral joints predicts atlantoaxial subluxations in patients with rheumatoid arthritis.
    Neva MH; Isomäki P; Hannonen P; Kauppi M; Krishnan E; Sokka T
    Arthritis Rheum; 2003 Jul; 48(7):1808-13. PubMed ID: 12847673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis.
    Welsing PM; Fransen J; van Riel PL
    Arthritis Rheum; 2005 Sep; 52(9):2616-24. PubMed ID: 16142762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.